NCT02961062View on ClinicalTrials.gov

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

January 15, 2018

Study Completion Date

February 21, 2018

Conditions
Postoperative Ocular Pain After PRK Surgery
Interventions
DRUG

SAF312

DRUG

Placebo

Trial Locations (4)

20815

Novartis Investigative Site, Chevy Chase

23502

Novartis Investigative Site, Norfolk

57108

Novartis Investigative Site, Sioux Falls

84020

Novartis Investigative Site, Draper

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY